News | October 12, 2025
Novo Nordisk to acquire Akero Therapeutics for $5.2 billion
Acquisition expands Novo Nordisk’s leadership in obesity-related comorbidities and metabolic diseases
Acquisition expands Novo Nordisk’s leadership in obesity-related comorbidities and metabolic diseases
UZEDY (risperidone) extended-release injectable suspension for subcutaneous use is indicated for use every one or two months for the treatment of schizophrenia in adults
The company will present new data from across over 20 cancer types and multiple treatment settings at European Society for Medical Oncology Congress 2025
Investigational cell therapy bemdaneprocel continues to demonstrate a favorable safety profile at 36 months in Phase I trial participants
First patients enrolled in Phase I trial with KQB548, an investigational KRAS inhibitor designed to treat KRAS G12D-mutated tumors
Facility marks cornerstone of $50 billion investment in medicines R&D and manufacturing in America
The company plans to use the funds raised from the net proceeds to repay or prepay certain loans
The initiative successfully demonstrates that used medical plastic packaging can be recycled and transformed back into new, contact-sensitive medical packaging
WHO’s global SPECS 2030 target to increase effective refractive error coverage by 40% by 2030
Lupin's partnership program is designed to foster collaborations with companies looking to extend their product lifecycles
Subscribe To Our Newsletter & Stay Updated
